“Why Has Kotak Upgraded Clean Science to Buy After a 20% Fall?”

Why Has Kotak Upgraded Clean Science to Buy despite Reducing Target?

Kotak’s New Target and Rating

Kotak Institutional Equities has upgraded Clean Science & Technology to Buy (from Reduce), setting a revised fair value target price of ₹1,370 compared to the earlier ₹1,380. The valuation is based on 30x Sept 2027E P/E.

Risk-Reward Turnaround

The stock corrected over 20% in just one month after the founding family’s 24% stake sale. With the sale now completed, Kotak sees the risk-reward ratio as more favourable, presenting an improved entry opportunity for investors.

Growth Pipeline and Estimates

Clean Science maintains a healthy pipeline of growth projects. Kotak has made modest tweaks to earnings estimates based on incremental disclosures, reinforcing confidence in the company’s medium-term growth trajectory.

Analyst Inputs — Quick Take

• The correction has reset valuations, making the stock more attractive near-term.
• The conclusion of the large stake sale removes a key supply overhang.
• The company’s diversified specialty chemicals portfolio positions it well for sustained growth.
• Key risks: execution delays in pipeline projects, raw material price volatility, and global demand slowdown.

Tags: Kotak, Clean Science, Target Price, Buy Rating, Specialty Chemicals, Risk Reward, Growth Projects

SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.

Written by Indian-Share-Tips.com, which is a SEBI Registered Advisory Services